Adverse Events as a Function of Biological Sex in a Multicenter Clinical Trial of Melanoma Vaccines is a research paper published in Cancers (2024). On theSindex it has a DataRank of 0. It has been cited 1 time.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
University of Virginia from Celldex (funding, drug), GSK (funding), Merck (funding, drug), 3M (drug), Theraclion (device staff support)
Grant: R01 CA118386
University of Virginia from Celldex (funding, drug), GSK (funding), Merck (funding, drug), 3M (drug), Theraclion (device staff support)
Grant: P30 CA044579
University of Virginia from Celldex (funding, drug), GSK (funding), Merck (funding, drug), 3M (drug), Theraclion (device staff support)
Grant: R25 CA206972
NCI NIH HHS
Grant: NCI R01 CA118386
National Institute of Health
Grant: NIH R25 CA206972
National Institutes of Health
Grant: 3P30CA044579-19S1
Cancer Center Support Grant
National Institutes of Health
Grant: 5R01CA118386-04
Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
National Institutes of Health
Grant: 5R25CA206972-07
Summer Research Experience in Cancer(SuRE-C)
University of Virginia from Polynoma for a PI role in the MAVIS Clinical Trial
University of Virginia for roles on the Scientific Advisory Boards for Immatics and CureVac
UVA Licensing and Ventures Group for patents for peptides used in cancer vaccines
University of Virginia from Celldex (funding, drug), GSK (funding), Merck (funding, drug), 3M (drug), Theraclion (device staff support)
FWCI
0.16
Citation Percentile
0.5%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals